Hospital Pedro Hispano

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis3 trials
• Epilepsy2 trials
• Idiopathic pulmonary fibrosis2 trials
• Lung cancer2 trials
• Stroke2 trials
• Atrial fibrillation1 trial
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 trial
• COPD1 trial
• Frontotemporal dementia1 trial
• Heart failure1 trial
• Irritable bowel syndrome1 trial
• Neuroendocrine tumours1 trial

Phase

• Phase 39 trials
• Phase 22 trials
• Phase 2/32 trials
• Phase 42 trials
• Phase 1/21 trial

Status

• Completed7 trials
• Active, not recruiting6 trials
• Recruiting3 trials

Lead sponsor

• Sanofi4 trials
• Biohaven Therapeutics Ltd.2 trials
• Boehringer Ingelheim2 trials
• Amgen1 trial
• Bayer AG1 trial
• and 6 more

Running trials

• Recruiting

  Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

  NCT07168434· Phase 3· Biocodex· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis

  2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Sanofi· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

  NCT05262023· Phase 1/2· Denali Therapeutics Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy1 recruiting
• Irritable bowel syndrome1 recruiting
• Stroke1 recruiting

Closed trials

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Active, not recruiting

  A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

  NCT06290128· Phase 3· Sanofi· Source

• Recruiting

  DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT05882058· Phase 2· Boehringer Ingelheim· Source

• Completed

  Initiation of ARNi and SGLT2i in Patients With HFrEF

  NCT05989503· Phase 4· Universidade do Porto· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

  NCT04751487· Phase 3· Sanofi· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source